PhotoPharmics: Funding, Investors & Team (Sep 2026)
PhotoPharmics is a medical device company in the clinical stage that is working on advanced treatments for neurodegenerative disorders by utilizing the eyes. The company is expanding its research to include other neurodegenerative diseases as well. In Parkinson's disease, PhotoPharmics has pioneered the use of specific light wavelengths and has successfully completed a key human clinical trial.
PhotoPharmics has raised $22.1M across 2 funding rounds on record, the most recent a Series B of $6.0M announced in Apr 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
PhotoPharmics Company Profile and Key Stats
Latest funding round on record: Apr 2025.
PhotoPharmics Funding Rounds
PhotoPharmics raised $16.1M in an undisclosed round announced in Nov 2023.
1.4 years later, a Series B of $6.0M was announced in Apr 2025.
PhotoPharmics Founders and Leadership Team
Contact details for the PhotoPharmics team: 1 of 1 has an email address on file.
Start 14-day free trial →PhotoPharmics Funding Compared to Other Biotechnology Startups
PhotoPharmics' latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like PhotoPharmics in Biotechnology and Lehi
Companies Similar to PhotoPharmics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
PhotoPharmics Funding FAQs
What does PhotoPharmics do?
PhotoPharmics is a medical device company in the clinical stage that is working on advanced treatments for neurodegenerative disorders by utilizing the eyes. The company is expanding its research to include other neurodegenerative diseases as well. In Parkinson's disease, PhotoPharmics has pioneered the use of specific light wavelengths and has successfully completed a key human clinical trial.
How much funding has PhotoPharmics raised?
PhotoPharmics has raised $22.1M across 2 rounds on record. The most recent is a Series B of $6.0M announced in Apr 2025.
When did PhotoPharmics last raise funding?
PhotoPharmics' most recent funding round on record is a Series B of $6.0M, announced in Apr 2025.
Who founded PhotoPharmics?
FundedIQ lists Kent Savage (Founder) at PhotoPharmics.
Where is PhotoPharmics headquartered?
PhotoPharmics is based in Lehi, Utah, United States.
How many employees does PhotoPharmics have?
PhotoPharmics is in the 1-10 employee band.
How does PhotoPharmics' funding compare to other Biotechnology startups?
PhotoPharmics' latest round of $6.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's PhotoPharmics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for PhotoPharmics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.